JPWO2021235044A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021235044A5 JPWO2021235044A5 JP2022514027A JP2022514027A JPWO2021235044A5 JP WO2021235044 A5 JPWO2021235044 A5 JP WO2021235044A5 JP 2022514027 A JP2022514027 A JP 2022514027A JP 2022514027 A JP2022514027 A JP 2022514027A JP WO2021235044 A5 JPWO2021235044 A5 JP WO2021235044A5
- Authority
- JP
- Japan
- Prior art keywords
- arteriosclerosis
- triglyceride
- accumulating
- agent according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010003210 Arteriosclerosis Diseases 0.000 claims 15
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 230000017531 blood circulation Effects 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 3
- 230000001373 regressive effect Effects 0.000 claims 3
- 238000009825 accumulation Methods 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000001631 haemodialysis Methods 0.000 claims 2
- 230000000322 hemodialysis Effects 0.000 claims 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims 2
- 229940093633 tricaprin Drugs 0.000 claims 2
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022127299A JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020090091 | 2020-05-22 | ||
| JP2020090091 | 2020-05-22 | ||
| JP2020192099 | 2020-11-18 | ||
| JP2020192099 | 2020-11-18 | ||
| PCT/JP2021/008689 WO2021235044A1 (ja) | 2020-05-22 | 2021-03-05 | 中性脂肪蓄積型動脈硬化退縮剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127299A Division JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021235044A1 JPWO2021235044A1 (cg-RX-API-DMAC7.html) | 2021-11-25 |
| JPWO2021235044A5 true JPWO2021235044A5 (cg-RX-API-DMAC7.html) | 2022-05-12 |
| JP7456662B2 JP7456662B2 (ja) | 2024-03-27 |
Family
ID=78708421
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514027A Active JP7456662B2 (ja) | 2020-05-22 | 2021-03-05 | 中性脂肪蓄積型動脈硬化退縮剤 |
| JP2022127299A Pending JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022127299A Pending JP2022166145A (ja) | 2020-05-22 | 2022-08-09 | 中性脂肪蓄積型動脈硬化退縮剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12576061B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4154877A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7456662B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021235044A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7236119B2 (ja) * | 2019-06-21 | 2023-03-09 | 学校法人近畿大学 | 大動脈瘤の予防用医薬組成物および加工食品 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393224B2 (en) * | 2011-08-26 | 2016-07-19 | Osaka University | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes |
-
2021
- 2021-03-05 WO PCT/JP2021/008689 patent/WO2021235044A1/ja not_active Ceased
- 2021-03-05 US US17/926,301 patent/US12576061B2/en active Active
- 2021-03-05 JP JP2022514027A patent/JP7456662B2/ja active Active
- 2021-03-05 EP EP21809755.8A patent/EP4154877A4/en active Pending
-
2022
- 2022-08-09 JP JP2022127299A patent/JP2022166145A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dellinger | Cardiovascular management of septic shock | |
| Van Crevel et al. | Clinical management of combined tuberculosis and diabetes | |
| JP2022009125A5 (cg-RX-API-DMAC7.html) | ||
| Carpentier et al. | Safety and tolerability of subcutaneous treprostinil in newborns with congenital diaphragmatic hernia and life-threatening pulmonary hypertension | |
| Bundgaard-Nielsen et al. | Orthostatic intolerance and the cardiovascular response to early postoperative mobilization | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2018172440A5 (cg-RX-API-DMAC7.html) | ||
| Cheng et al. | The response to methylene blue in patients with severe hypotension during liver transplantation | |
| Musso et al. | Therapeutic alternatives and palliative care for advanced renal disease in the very elderly: a review of the literature | |
| JP2017014206A5 (cg-RX-API-DMAC7.html) | ||
| Ermolova et al. | Correction of intrahepatic microcirculation disorders by L-ornithine-L-aspartate at the chronic liver diseases patients | |
| Zhao et al. | Septic shock due to community‑acquired Pseudomonas aeruginosa necrotizing fasciitis: A case report and literature review | |
| Su et al. | The current opinions of capillary leak syndrome | |
| ECSP055914A (es) | Combinación farmacéutica para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales | |
| Mathur et al. | Comparison of norepinephrine and dopamine in the management of septic shock using impedance cardiography | |
| Yanase et al. | A comparison of the hemodynamic effects of fluid bolus therapy with crystalloids vs. 4% albumin and vs. 20% albumin in patients after cardiac surgery | |
| JP2023060011A5 (cg-RX-API-DMAC7.html) | ||
| Karnad et al. | Continuous renal replacement therapy may aid recovery after cardiac arrest | |
| JP2018523711A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020166557A5 (cg-RX-API-DMAC7.html) | ||
| Wilhelm | Epidural anesthesia for cesarean delivery facilitated by minimally invasive hemodynamic monitoring in a patient with Fontan repair: a case report. | |
| Kurhekar et al. | Myocardial stunning after resuscitation from cardiac arrest following spinal anaesthesia | |
| Kogelmann et al. | Successful treatment with Cytosorb in a case of septic shock, ARDS, multiorgan failure and pur-pura fulminans due to Acinetobacter baumannii pneumonia | |
| Nur et al. | PHARMACEUTICAL MARKET IN MALAYSIA | |
| Artikova et al. | PROBLEMS IN THE TREATMENT OF HYPERTENSION AND METHODS OF THEIR ELIMINATION |